Cellular MRI and its role in stem cell therapy

Regenerative Medicine

Volumn 3, Issue 2, 2008, Pages 199-215

  Arbab, Ali S ^a   Frank, Joseph A ^b  

^a HENRY FORD HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cellular MRI; Ferumoxides protamine sulfate; Magnetic cell labeling; SPIO; Stem cell tracking

Indexed keywords

ADENOVIRUS VECTOR; CONTRAST MEDIUM; FIALURIDINE; FLUORINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL; INDIUM 111; IODINE 123; IODINE 131; IRON; MANGANESE CHLORIDE; PROTAMINE SULFATE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TECHNETIUM 99M; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CELL HOMING; CELL LABELING; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; MOLECULAR PROBE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROMA CELL;

ANIMALS; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RATS; STEM CELL TRANSPLANTATION;

EID: 42249115060     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.2.199     Document Type: Review

References (192)

1. Schachinger V, Erbs S, Elsasser A et al.: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210-1221 (2006).
2. Osterziel KJ: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1 year results of the REPAIR-AMI trial. Eur. Heart J. 28, 638 (2007).
3. Schachinger V, Erbs S, Elsasser A et al.: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 27, 2775-2783 (2006).
4. Cleland JG, Freemantle N, Coletta AP, Clark AL: Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 8, 105-110 (2006).
5. Henningson CT Jr, Stanislaus MA, Gewirtz AM: 28. Embryonic and adult stem cell therapy. J. Allergy Clin. Immunol. 111, S745-S753 (2003).
6. Burt R, Pearce W, Luo K et al.: Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease. Bone Marrow Transplant. 32 (Suppl. 1), S29-S31 (2003).
7. Perin EC, Silva GV: Stem cell therapy for cardiac diseases. Curr. Opin. Hematol. 11, 399-403 (2004).
8. Perin EC, Dohmann HF, Borojevic R et al.: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure [see comment]. Circulation 107, 2294-2302 (2003).
9. Amrani DL, Port S: Cardiovascular disease: potential impact of stem cell therapy. Expert Rev. Cardiovasc. Ther. 1, 453-461 (2003).
10. Kawamoto A, Tkebuchava T, Yamaguchi J et al.: Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107, 461-468 (2003).
11. Manganas LN, Maletic-Savatic M: Stem cell therapy for central nervous system demyelinating disease. Curr. Neurol. Neurosci. Rep. 5, 225-231 (2005).
12. Shah K, Bureau E, Kim DE et al.: Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol. 57, 34-41 (2005).
13. Reinlib L, Field L: Cell transplantation as future therapy for cardiovascular disease? a workshop of the National Heart, Lung, and Blood Institute. Circulation 101, e182-e187 (2000).
14. + cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin. Cancer Res. 6, 4442-4448 (2000).
15. Griese DP, Achatz S, Batzisperger CA et al.: Vascular gene delivery of anticoagulants by transplantation of retrovirally-transduced endothelial progenitor cells. Cardiovasc. Res. 58, 469-477 (2003).
16. Komarova S, Kawakami Y, Stoff-Khalill MA, Curiei DT, Pereboeva L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5, 755-766 (2006).
17. Zhou H, Ramiya VK, Visner GA: Bone marrow stem cells as a vehicle for delivery of heme oxygenase-1 gene. Stem Cells Dev. 15, 79-86 (2006).
18. Muller FJ, Snyder EY, Loring JF: Gene therapy: can neural stem cells deliver? Nat. Rev. Neurosci. 7, 75-84 (2006).
19. Kabos P, Ehtesham M, Black KL, Yu JS: Neural stem cells as delivery vehicles. Expert Opin. Biol. Ther. 3, 759-770 (2003).
20. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Therapy 7, 43-52 (2000).
21. Kim DE, Tsuji K, Kim YR et al.: Neural stem cell transplant survival in brains of mice: assessing the effect of immunity and ischemia by using real-time bioluminescent imaging. Radiology 241, 822-830 (2006).
22. Li Z, Wu JC, Sheikh AY et al.: Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation 116, 146-154 (2007).
23. Zhang SJ, Wu JC: Comparison of imaging techniques for tracking cardiac stem cell therapy. J. Nucl. Med. 48, 1916-1919 (2007).
24. Brazelton TR, Blau HM: Optimizing techniques for tracking transplanted stem cells in vivo. Stem Cells 23, 1251-1265 (2005).
25. Blits B, Kitay BM, Farahvar A, Caperton CV, Dietrich WD, Bunge MB: Lentiviral vector-mediated transduction of neural progenitor cells before implantation into injured spinal cord and brain to detect their migration, deliver neurotrophic factors and repair tissue. Restor. Neurol. Neurosci. 23, 313-324 (2005).
26. Tanaka M, Swijnenburg RJ, Gunawan F et al: In vivo visualization of cardiac allograft rejection and trafficking passenger leukocytes using bioluminescence imaging. Circulation 112, 1105-110 (2005).
27. Paulmurugan R, Garnbhir SS: Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal. Chem, 77, 1295-1302 (2005).
28. Dingli D, Peng KW, Harvey ME et al.: Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem. Biophys. Res. Commun. 337, 22-29; (2005).
29. Kim DE, Jaffer FA, Weissleder R, Tung CH, Schellingerhout D: Near-infrared fluorescent imaging of cerebral thrombi and blood-brain barrier disruption in a mouse model of cerebral venous sinus thrombosis. J. Cereb. Blood Flow Metab. 25, 226-233 (2005).
30. Chung JK: Sodium Iodide symporter: its role in nuclear medicine. J. Nucl. Med. 43, 1188-1200 (2002).
31. Yaghoubi SS, Barrio JR, Namavari M et al.: Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 12, 329-339(2005).
32. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in vitro compararison-with other PET tracers. Nucl. Med. Commun. 27, 25-30 (2006).
33. Hustinx R, Shiue CY, Alavi A et al.: Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography. Eur. J Nucl. Med. 28, 5-12 (2001).
34. Cao F, Lin S, Xie X et al: In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113, 1005-1014 (2006).
35. Okada S, Ishii K, Yamane J et al: In vivo imaging of engrafted neural stem cells: its application in evaluating the optimal timing of transplantation for spinal cord injury. FASEB J. 19, 1839-1841 (2005).
36. Edinger M, Hoffmann P, Contag CH, Negrin RS: Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 31, 172-179 (2003).
37. Lin S, Xie X, Patel MR et al.: Quantum dot imaging for embryonic stem cells. BMC Biotechnol. 7, 67 (2007).
38. Lei Y, Tang H, Yao L, Yu R, Feng M, Zou B: Applications of mesenchymal stem cells labeled with tat peptide conjugated quantum dots to cell tracking in mouse body. Bioconjug. Chem. (2007) (Epub ahead of print).
39. Bruchez MP: Turning all the lights on: quantum dots in cellular assays. Curr. Opin. Chem. Biol. 9, 533-537 (2005).
40. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E: Nanocrystal targeting in vivo. Proc. Natl Acad. Sci. USA 99, 12617-12621 (2002).
41. Michalet X, Pinaud FF, Bentolila LA et al.: Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544 (2005).
42. Potapova IA, Gaudette GR, Brink PR et al.: Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 25, 1761-1768 (2007).
43. Rosen AB, Kelly DJ; Schuldt AJ et al.: Finding fluorescent needles in the cardiac haystack: tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis. Stem Cells 25, 2128-2138 (2007).
44. Frank JA, Zywicke H, Jordan EK et al.: Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad. Radiol. 9(Suppl. 2), S484-S487 (2002).
45. Frank JA, Miller BR, Arbab AS et al.: Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 228, 480-487 (2003).
46. Arbab AS, Jordan EK, Wilson LB, Yoeum GT, Lewis BK, Frank JA: In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther. 15, 351-360 (2004).
47. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA: Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 76, 1123-1130 (2003).
48. Modo M, Hoehn M, Bulte JW: Cellular MR imaging. Mol. Imaging 4, 143-164 (2005).
49. Bulte JW, Arbab AS, DouglasT Frank JA: Preparation of magnetically labeled cells for cell tracking by mgnetic resonance imaging. Meth. Enzymol. 386, 275-299 (2004).
50. Bulte JW. Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17, 484-499 (2004).
51. Foster-Gareau P, Heyn C, Alejski A, Rutt BK: Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn. Reson. Med. 49, 968-971 (2003).
52. Shapiro EM, Sharer K. Skrtic S, Koretsky AP: In vivo detection of single cells by MRI. Magn. Reson. Med. 55, 242-249 (2006).
53. Arbab AS, Bashaw LA, Miller BR et al.: Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging [see comment]. Radiology 229, 838-846 (2003).
54. Arbab AS, Yocum GT, Kalish H et al.: Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI [see comment). Blood 104, 1217-1223 (2004).
55. Arbab AS, Yocum GT, Wilson LB et al.: Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol. Imaging 3, 24-32 (2004).
56. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L: A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Rev. 63, 8122-8125 (2003).
57. + T-cells to the pancreas in real time. Diabetes 53, 1459-1466 (2004).
58. Josephson L, Tung CH, Moore A, Weissleder R: High-efficiency Intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 10, 186-191 (1999).
59. Walczak P, Kedziorek DA, Gilad AA, Lin S, Bulte JW. Instant MR labeling of stem cells using magnetoelectroporation. Magn. Reson. Med. 54, 769-774 (2005).
60. Toyoda K, Tooyama I, Kato M et al.: Effective magnetic labeling of transplanted cells with HVJ-E for magnetic resonance imaging. Neuroreport 15, 589-593 (2004).
61. van den Bos EJ, Wagner A, Mahrholdt H et al.: Improved efficacy of stem cell labeling for magnetic resonance imaging studies by the use of cationic liposomes. Cell Transplant. 12, 743-756 (2003).
62. Shapiro EM, Skrtic S, Koretsky AP: Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn. Reson. Med. 53, 329-338 (2005).
63. Zheng H, Youdim MB, Weiner LM, Fridkin M: Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem. Pharmacol. 70, 1642-1652 (2005).
64. Vuu K, Xie J, McDonald MA et al.: Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug. Chem. 16, 995-999 (2005).
65. Anderson SA, Lee KK, Frank JA: Gadolinium-fullerenol as a, paramagnetic contrast agent for cellular imaging. Invest. Radiol. 41, 332-338 (2006).
66. Rudelius M, Daldrup-Link HE, Heinzmann U et al.: Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. Eur J. Nucl. Med. Mol. Imaging 30, 1038-1044 (2003).
67. Aime S, Barge A, Cabella C, Crich SG, Gianolie, E: Targeting cells with MR imaging probes based on paramagnetic G(III) chelates. Curr Pharm. Biotechnol. 5, 509-518 (2004).
68. Aoki I, Takahashi Y, Chuang KH et al.: Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride. NMR Biomed. 19, 50-59 (2006).
69. Crich SG, Biancone L, Cantaluppi V et al.: Improved route for the visualization of stem cells labeled with a Gd-/Eu-chelate as dual (MRI and fluorescence) agent. Magn. Reson. Med. 51, 938-944 (2004).
70. Zheng Q, Dai H, Merritt ME, Malloy C, Pan CY, Li WH: A new class of macrocyclic lanthanide complexes for cell labeling and magnetic resonance imaging applications. J Am. Chem. Soc. 127, 16178-16188 (2005).
71. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M: In vivo imaging of the systemic recruitment of fibroblasts to the anglogenic rim of ovarian carcinoma tumors. Cancer Res. 67, 9180-9189 (2007).
72. Granot D, Kunz-Schughart LA, Neeman M: Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging. Magn. Reson. Med. 54, 789-797 (2005).
73. Su W, Mishra R, Pfeuffer J, Wiesmuller KH, Ugurbil K, Engelmann J: Synthesis and cellular uptake of a MR contrast agent coupled to an antisense peptide nucleic acid-cell-penetrating peptide conjugate. Contrast Media Mol. Imaging 2, 42-49 (2007).
74. Giesel FL, Stroick M, Griebe M et al.: Gadofluorine m uptake in stem cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo study. Invest Radiol. 41, 868-873 (2006).
75. Himmelreich U, Aime S, Hieronymus T et al.: A responsive MRI contrast agent to monitor functional cell status. Neuroimage 32, 1142-1149 (2006).
76. Daldrup-Link HE, Rudelius M, Metz S et al.: Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur. J. Nucl. Med. Mol. Imaging 31, 1312-1321 (2004).
77. Brekke C, Morgan SC, Lowe AS et al.: The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry. NMR Biomed. 20, 77-89 (2007).
78. Modo M, Mellodew K, Cash D et al.: Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage 21, 311-317 (2004).
79. Modo M, Cash D, Mellodew K et al.: Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. Neuroimage 17, 803-811 (2002).
80. Grobner T, Prischl FC: Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 721 260-264 (2007).
81. Wolf GL, Burnett KR, Goldstein EJ, Joseph PM: Contrast agents for magnetic resonance imaging. Magn. Reson. Annu. 1985, 231-266.
82. Mendonca-Dias MH, Gaggelli E, Lauterbur PC: Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. Semin. Nucl. Med. 13, 364-376. (1983).
83. Na HB, Lee JH, An K et al.: Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew. Chem. Int. Ed. Engl. 46, 5397-5401 (2007).
84. Arbab AS, Pandit SD, Anderson SA et al.; Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 24, 671-678 (2006).
85. Bulte JW, DouglasT, Witwer B et al.: Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 19, 1141-1147 (2001).
86. Bulte JW, Zhang S, van Geideren P et al.; Neurotransplantatian of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc. Natl Acad. Sci. USA 96, 15256-15261 (1999).
87. Anderson SA, Shukaliak-Quandt J, Jordan EK et al.: Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann. Neurol. 55, 654-659 (2004).
88. Anderson SA, Glod J, Arbab AS et al.: Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105, 420-425 (2005).
89. Oweida AJ, Dunn EA, Foster PJ: Cellular imaging at 1.5 T detecting cells in neuroinflammation using active labeling with superparamagnetic iron oxide. Mol. Imaging 3, 85-95 (2004).
90. Daldrup-Link HE, Rudelius M, Piontek G et al.: Migration of iron oxide-labeled human hematopoletic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology 234, 197-205 (2005).
91. Daldrup-Link HE, Rudelius M, Oostendorp RA et al.: Targeting of hematopoletic progenitor cells with MR contrast agents. Radiology 228, 760-767 (2003).
92. Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A: In vivo imaging of islet transplantation. Nat Med. 12, 144-148 (2006).
93. Moore A, Sun PZ, Coyy D, Hogemann D, Weissleder R, Lipes MA: MRI of insulitis in autoimmune diabetes. Magn. Reson. Med. 47, 751-758 (2002).
94. Tai JH, Foster P, Rosales A et al.: Imaging islets labeled with magnetic nanoparticles at 1.5 Tesia. Diabetes 55, 2931-2938 (2006).
95. Heyn C, Ronald JA, Mackenzie LT et al.: In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn. Reson. Med. 55, 23-29 (2006).
96. Shapiro EM, Gonzalez-Perez O, Manuel Garcia-Verdugo J, Alvarez-Buylla A, Koretsky AP: Magnetic resonance imaging of the migration of neuronal precursors generated in the adult rodent brain. Neuraimage 32, 1150-1157 (2006).
97. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP: MRI deiection of single particles for cellular imaging. Proc. Natl Acad. Sci. USA 101, 10901-10906 (2004).
98. Hinds KA, Hill JM, Shapiro EM et al.: Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 102, 867-872 (2003).
99. Arbab AS, Yocum GT Rad AM et al.: Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoletic or mesenchymal stem cells. NMR Biomed. 18, 553-559 (2005).
100. Arbab AS, Yocum GT, Kalish H et al.: Ferumoxides-protaxydne sulfate labeling does not alter differentiation of mesenchymal stem cells. Blood 104, 3412-3413 (2004).
101. Guzman R, Uchida N, Bliss TM et al.: Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc. Natl Acad. Sci. USA 104, 10211-10216 (2007).
102. Suzuki Y, Zhang S, Kundu P, Yeung AC, Robbins RC, Yang PC: In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides. Magn. Reson. Med. 57, 1173-1179 (2007).
103. Pawelczyk E, Arbab AS, Pandit S, Hu E, Frank JA: Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed. 19, 581-592 (2006).
104. Arbab AS, Wilson LB, Ashari R Jordan EK, Lewis BK, Frank JA: A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 18, 383-389 (2005).
105. Heyn C, Ronald JA, Ramadan SS et al.: In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson Med. 56, 1001-1010 (2006).
106. Cohen B, Dafni H, Meir G, Harmelin, A, Neeman M: Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 7, 109-117 (2005).
107. Cohen B, Ziv K, Plaks V et al.: MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med. 13, 498-503 (2007).
108. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med. 11, 450-454 (2005).
109. Marsh JN, Partlow KC, Abendschein DR, Scott MJ, Lanza GM, Wickline SA: Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration, dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med. Biol. 33, 950-958 (2007).
110. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 21, 1647-1654 (2007).
111. Contag CH, Jenkins D, Contag PR, Negrin RS: Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2, 41-52 (2000).
112. Yu YA, Timiryasova T, Zhang Q, Beltz R, Szalay AA: Optical imaging: bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals. Anal. Bioanal. Chem. 377, 964-972 (2003).
113. Choy G, O'Connor S, Diehn FE et al.: Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35, 1022-1026, 1028-1030 (2003).
114. Choy G, Choyke P, Libutti SK: Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol. Imaging 2, 303-312 (2003).
115. Funovics MA, Welssleder R. Mahmood U: Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology 231, 659-666 (2004).
116. Hakamata Y, Murakami T, Kobayashi E: 'Firefly rats' as an organ/cellular source for long-term in vivo bioluminescent imaging. Transplantation 81, 1179-1184 (2006).
117. Schellingerhout D, Josephson L: Molecular imaging of cell-based therapies. Neuroimaging Clin. N. Am. 14, 331-342, ix (2004).
118. Shah K, Jacobs A, Breakefield XO, Weissleder R: Molecular imaging of gene therapy for cancer. Gene Therapy 11, 1175-1187 (2004).
119. Shah K: Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol. Ther. 4, 518-523 (2005).
120. Shah K, Tung CH, Breakefield XO, Weissleder R: In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther. 11, 926-931 (2005).
121. Sheikh AY, Wu JC: Molecular imaging of cardiac stem cell transplantation. Curr. Cardiol. Rep. 8, 147-154 (2006).
122. Hoshino K, Ly HQ, Frangioni JV, Hajjar RJ: In vitro tracking in cardiac stem cell-based therapy. Prog. Cardiovasc. Dis. 49, 414-420 (2007).
123. Morawski AM, Lanza GA, Wickline SA: Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr. Opin. Biotechnol. 16, 89-92 (2005).
124. Bara C, Ghodsizad A, Niehaus M et al.: In vivo echocardiographic imaging of transplanted human adult stem cells in the myocardium labeled with clinically applicable CliniMACS nanoparticles. J. Am. Soc. Echocardiogr. 19, 563-568 (2006).
125. Rome C, Couillaud F, Moonen CT: Gene expression and gene therapy imaging. Eur. Radiol. 17, 305-319 (2007).
126. Sykova E, Jendelova P: In vivo tracking of stem cells in brain and spinal cord injury. Prog. Brain Res. 161, 367-383 (2007).
127. Aicher A, Brenner W, Zuhayra M et al.: Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107, 2134-2139 (2003).
128. 111 In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl. Med. Commun. 24, 1149-1154 (2003).
129. + peripheral blood stem cells after intracoronary administration in patients with chronic ischemic heart disease. Q. J. Nucl. Med. Mol. Imaging 51, 61-66 (2007).
130. Bindslev L, Haack-Sorensen M, Bisgaard K et al.: Labelling of Human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. Eur. J. Nucl. Med. Mol. Imaging 33, 1171-1177 (2006).
131. Read EJ, Keenan AM, Carter CS, Yolles PS, Davey RJ: In vivo traffic of indium-111 -oxine labeled human lymphocytes collected by automated apheresis. J. Nucl. Med. 31, 999-1006 (1990).
132. Griffith KD, Read EJ, Carrasquillo JA et al: In vivo distribution of adoptively transferred indium- 111 -labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81, 1709-1717 (1989).
133. Fisher B, Packard BS, Read EJ et al.: Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7, 250-261 (1989).
134. Read EJ, Carter CS: Radiolabeled platelet survival studies. Transfusion 26, 490-491 (1986).
135. Schauwecker DS, Leapman SB, Siddiqui AR, Filo RS, Smith PG, Forney MN: Evaluation of In-111 labeled lymphocytes in an acute rejection model. J. Med. 14, 103-116 (1983).
136. Lerch RA, Bergmann SR, Carlson EM, Saffitz JE, Sobel BE: Monitoring of cardiac antirejection therapy with In-111 lymphocytes. J. Nucl. Med. 23, 496-500 (1982).
137. Chisholm PM, Danpure HJ, Healey G, Osman S: Cell damage resulting from the labeling of rat lymphocytes and HeLa S3 cells with In-111 oxine. J. Nucl. Med. 20, 1308-1311 (1979).
138. 177Lu? J. Nucl. Med. 46, 634-641 (2005).
139. 111In-labelled NK cells in patients with renal cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31, 403-407 (2004).
140. Berry CR, Fisher P, Koblik PD, Guilford WG, Hornof WH: Scintigraphic biodistribution and plasma kinetics of indium 111-labeled transferrin in dogs. Am. J. Vet. Res. 58, 1188-1192 (1997).
141. Oyen WJ, Claessens RA, van der Meer JW, Corstens FH: Biodistribution and kinetics of radiolabeled proteins in rats with focal infection. J. Nucl. Med. 33, 388-394 (1992).
142. Kraitchman DL, Tatsumi M, Gilson WD et al.: Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 112, 1451-1461 (2005).
143. Nowak B, Weber C, Schober A et al.: Indium- 111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells. Eur. J. Nucl. Med. Mol. Imaging 34, 715-721 (2007).
144. + hematopoietic progenitor cells in a rat myocardial infarction model. J. Nucl. Med. 45, 512-518 (2004).
145. Niu G, Anderson RD, Madsen MT, Graham MM, Oberley LW, Domann FE: Dual-expressing adenoviral vectors encoding the sodium iodide symporter for use in noninvasive radiological imaging of therapeutic gene transfer. Nucl. Med. Biol. 33, 391-398 (2006).
146. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC: Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 13, 60-66 (2006).
147. Lee WW, Moon DH, Park SY, Jin J, Kim SJ, Lee H: Imaging of adenovirus-mediated expression of human sodium iodide symporter gene by 99mTcO4 scintigraphy in mice. Nucl. Med. Biol. 31, 31-40 (2004).
148. Koehne G, Doubrovin M, Doubrovina E et al.: Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat. Biotechnol. 21, 405-413 (2003).
149. Hofmann M, Wollert KC, Meyer GP et al.: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198-2202 (2005).
150. Frangioni JV, Hajjar RJ: In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 110, 3378-3383 (2004).
151. Ma B, Hankenson KD, Dennis JE, Caplan AI, Goldstein SA, Kilbourn MR: A simple method for stem cell labeling with fluorine 18. Nucl. Med. Biol. 32, 701-705 (2005).
152. 64Cu-pyruvaldehydebis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with postron-emission tomography. Proc Natl Acad. Sci. USA 99, 3030-3035 (2002).
153. Acton PD, Zhou R: Imaging reporter genes for cell tracking with PET and SPECT. Q. J. Nucl. Med. Mol. Imaging 49, 349-360 (2005).
154. Wu JC, Cao F, Dutta S et al.: Proteomic analysis of reporter genes for molecular imaging of transplanted embryonic stem cells. Proteomics 6, 6234-6249 (2006).
155. van der Bogt KE, Swijnenburg RJ, Cao F, Wu JC: Molecular imaging of human embryonic stem cells: keeping an eye on differentiation, tumorigenicity and immunogenicity. Cell Cycle 5, 2748-2752 (2006).
156. Cao F, Drukker M, Lin S et al.: Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. Cloning Stem Cells 9, 107-117 (2007).
157. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM: Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53, 999-1005 (2005).
158. Seppenwoolde JH, Viergever MA, Bakker CJ: Passive tracking exploiting local signal conservation: the white marker phenomenon. Magn. Reson. Med. 50, 784-790 (2003).
159. Liu W, Dahnke H, Jordan EK, Schaeffter T. Frank JA: In vivo MRI using positive-contrast techniques in detection of cells labeled with superparamagnetic iron oxide nanoparticles. NMR Biomed. (2007) (Epub ahead of print).
160. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA: Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn. Reson. Med. 37, 530-536 (1997).
161. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK: Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson. Med. 48, 52-61 (2002).
162. Rad AM, Arbab AS, Iskander AS, Jiang Q, Soltanian-Zadeh H: Quantification of superparamagnetic iron oxide (SPIO)-labeled cells using MRI. J. Magn. Reson. Imaging 26, 366-374 (2007).
163. Dahnke H, Schaeffter T: Limits of detection of SPIO at 3.0 T using T2 relaxometry. Magn. Reson. Med. 53, 1202-1206 (2005).
164. Ko IK, Song HT Cho EJ, Lee ES, Huh YM, Sub JS: In vivo MR imaging of tissue-engineered human mesenchymal stem cells transplanted to mouse: a preliminary study. Ann. Biomed. Eng. 35, 101-108 (2007).
165. Terrovitis JV, Bulte JW, Sarvananthan S. et al.: Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells seeded on collagen scaffolds-relevance to tissue engineering. Tissue Eng. 12, 2765-2775 (2006).
166. Kraitchman DL, Heldman AW, Atalar E et al.: In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107, 2290-2293 (2003).
167. Amado LC, Schuleri KH, Saliaris AP et al.: Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J. Am. Coll. Cardiol. 48, 2116-2124 (2006).
168. Amsalem Y, Mardor Y, Feinberg MS et al.: Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation 116, 138-45 (2007).
169. Hoehn M, Kustermann E, Blunk J et al.: Monitoring of implanted stem cell migration in vivo a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc. Natl Acad. Sci. USA 99, 16261-16272 (2002).
170. Gao F, Kar S, Zhang J et al., MRI of intravenously injected bone marrow cells homing to the site of injured arteries. NMR Biomed. 20, 673-681 (2007).
171. Qiu B, Gao F, Walczak P et al.: In vivo MR imaging of bone marrow cells trafficking to atherosclerotic plaques. J. Main. Reson. Imaging 26, 339-343 (2007).
172. de Vries IJ, Lesterhuis WJ, Barentsz JO et al.: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23, 1407-1413 (2005).
173. Zhu J, Zhou L, Xing Wu F: Tracking neural stem cells in patients with brain trauma, N. Engl. J. Med. 355, 2376-2378 (2006).
174. Burns TC, Ortiz-Gonzalez XR, Gutierrez-Perez M et al.: Thymidine analogs are transferred from prelabeled donor to host cells in the central nervous system after transplantation: a word of caution. Stem Cells 24, 1121-1127 (2006).
175. Rieck B, Schlaak S: Measurement in vivo of the survival rate in autologous adipocyte transplantation. Plast. Reconstr, Surg. 111, 2315-2323 (2003).
176. Ebert SN, Taylor DG, Nguyen HL et al.: Noninvasive tracking of cardiac embryonic stem cells in vivo using magnetic resonance imaging techniques. Stem Cells 25, 2936-2944 (2007).
177. Tallheden T, Nannmark U, Lorentzon M et al.: In vivo MR imaging of magnetically labeled human embryonic stem cells. Life Sci. 79, 999-1006 (2006).
178. Rogers WJ, Meyer CH, Kramer CM: Technology insight: in vivo cell tracking by use of MRI. Nat Clin. Pract. Candiovasc. Med. 3, 554-562 (2006).
179. Lepore AC, Walczak P, Rao MS, Fischer I, Bulte JW: MR imaging of lineage-restricted neural precursors following transplantation into the adult spinal cord. Exp. Neurol. 201, 49-59 (2006).
180. Cahill KS, Germain S, Byrne BJ, Walter GA: Non-invasive analysis of myoblast transplants in rodent cardiac muscle. Int. J. Cardiovasc. Imaging 20, 593-598 (2004).
181. Evgenov NV, Medarova Z, Pratt J et al.: In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes 55, 2419-2428 (2006).
182. Molcanyi M, Riess P, Bentz K et al.: Trauma-associated inflammatory response impairs embryonic stem cell survival and integration after implantation into injured rat brain. J. Neurotrauma 24, 625-637 (2007).
183. Pawelczyk E, Arbab AS, Chaudhry A, Balakumaran A, Robey PG, Frank JA: In vitro model of BrdU or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells (2008) (In Press).
184. Zhang R, Zhang Z, Wang L et al.: Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J Cereb. Blood Flow Metab. 24, 441-448 (2004).
185. Jiang Q, Zhang ZG, Ding GL et al.: Investigation of neural progenitor cell induced angiogenesis after embolic stroke in rat using MRI. Neuroimage 28, 698-707 (2005).
186. Chen J, Zhang ZG, Li Y et al.: Intravenous administration of human bone marrow stromal cells induces angiogenesis in the Ischemic boundary zone after stroke in rats [see comment). Circ. Res. 92, 692-699 (2003).
187. Chen J, Li Y, Katakowski M et al.: Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J. Neurosci. Res. 73, 778-786 (2003).
188. Li Y, Chen J, Chen XG et al.: Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery [see comment]. Neurology 59, 514-523 (2002).
189. Schuster MD. Kocher AA, Seki T et al.: Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am. J. Physiol. Heart Circ. Physiol. 287, H525-532 (2004).
190. Zeng L, Hu Q, Wang X et al.: Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115, 1866-1875 (2007).
191. Ye Y, Bogaert J: Cell therapy in myocardial infarction: emphasis on the role of MRI. Eur. Radiol. (2007) (Epub ahead of print).
192. Zhang ZG, Jiang Q, Zhang R et al.: Magnetic resonance Imaging and neurosphere therapy of stroke in rat. Ann. Neurol. 53, 259-263 (2003).